Skip to main content

Erratum to: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

It has been brought to our attention that there was a typographical error in our recent article [1] published in March 2006.

In the Conclusions section the final sentence should read:

Questions such as the optimal duration of therapy and efficacy in stage I disease remain to be answered.

References

  1. 1.

    Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research. 2006, 8: R13-10.1186/bcr1384.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Trevor Powles.

Additional information

The online version of the original article can be found at 10.1186/bcr1384

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Powles, T., Paterson, A., McCloskey, E. et al. Erratum to: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8, 406 (2006). https://doi.org/10.1186/bcr1413

Download citation